No Data
No Data
Analysts Have Conflicting Sentiments on These Healthcare Companies: AlloVir (ALVR), Guardant Health (GH) and Centessa Pharmaceuticals (CNTA)
AlloVir | 10-Q: Quarterly report
Maintaining a Hold: AlloVir's Strategic Uncertainty and Financial Outlook
ALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
AlloVir Faces Delisting Risk, Considers Reverse Split to Comply
AlloVir(ALVR.US) Officer Sells US$7,493.92 in Common Stocks
$AlloVir(ALVR.US)$ Officer Hagen Brett R sold 11,150 shares of Common Stocks on Feb 8, 2024 at an average price of $0.6721 for a total value of $7,493.92.Source: Announcement What is statement of chan
No Data